Patents by Inventor Jeffrey J. Seilhamer

Jeffrey J. Seilhamer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5780268
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode TMEC, a novel human lymphotactin expressed in T-cell mixed lymphocyte reaction (TMLR). The present invention also provides for polymerase chain reaction oligomers or hybridization probes for the detection of nucleotide sequences encoding TMEC or TMEC-like molecules, antisense molecules to the nucleotide sequences which encode TMEC, diagnostic tests based on TMEC encoding nucleic acid molecules, genetically engineered expression vectors and host cells for the production of purified TMEC, antibodies capable of binding specifically to TMEC, antagonists and inhibitors with specific binding activity for TMEC, and treatment methods.
    Type: Grant
    Filed: December 6, 1995
    Date of Patent: July 14, 1998
    Assignee: Incyte Pharmaceuticals
    Inventors: Roger Coleman, Karl J. Guegler, Jeffrey J. Seilhamer
  • Patent number: 5756333
    Abstract: Recombinant methods and materials useful in producing lactoperoxidases are disclosed. An illustrative form of lactoperoxidase is the bovine protein shown in FIG. 1. FIG. 1 also shows the DNA sequence natively encoding the bovine lactoperoxidase, including contiguous regions of the gene. Such DNAs are useful in a variety of applications including antisense technology, formation of triple helices, and performance of diagnostic assays.
    Type: Grant
    Filed: July 11, 1994
    Date of Patent: May 26, 1998
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Jeffrey J. Seilhamer, Thomas J. Dull
  • Patent number: 5710257
    Abstract: Pharmaceutical compositions useful in the treatment of autoimmune conditions include as an active ingredient a soluble lectin having a molecular weight of about 14 kilodaltons or a fragment thereof. The lectin or fragment binds .beta.-galactoside-containing moieties independent of the presence or absence of Ca.sup.+2, stimulates hemagglutination of trypsinized rabbit erythrocytes in standard lectin assays wherein the stimulation is inhibited by lactose or thiogalactoside, has an amino acid sequence containing at least one N-glycosylation site and is at least 90% homologous to the amino acid sequence shown in positions 2-135 of FIG. 1 or the relevant portions thereof. The composition is used for treatment of autoimmune conditions such as rheumatoid arthritis, myasthenia gravis, and multiple sclerosis, as well as modulating the immune response in an allergic reactions or to organ or tissue transplant rejection. The inventive composition can be combined with general immunosuppressants.
    Type: Grant
    Filed: September 25, 1996
    Date of Patent: January 20, 1998
    Inventors: Jeffrey J. Seilhamer, Glenn Nedwin, Tim Bringman, Pierre-Olivier Couraud
  • Patent number: 5686597
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel thrombin receptor homolog (TRH) expressed in human liver. The present invention also provides for antisense molecules to the nucleotide sequences which encode TRH, diagnostic tests based on TRH encoding nucleic acid molecules, expression vectors for the production of purified TRH, antibodies capable of binding specifically to TRH, hybridization probes or oligonucleotides for the detection of TRH-encoding nucleotide sequences, genetically engineered host cells for the expression of TRH, and antagonists, antibodies and inhibitors with specific binding activity for the polypeptide TRH.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 11, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Janice Au-Young, Olga Bandman, Jeffrey J. Seilhamer
  • Patent number: 5676946
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel phospholipase C homolog (plch and PLCH). The present invention also provides for antisense molecules to the plch nucleotide sequences, expression vectors for the production of purified PLCH, antibodies capable of binding specifically to PLCH, hybridization probes or oligonucleotides for detecting excess PLCH-encoding nucleotide sequences, genetically engineered host cells for the expression of PLCH, diagnostic tests for activated, inflamed, diseased, and hydroxyurea-resistant cells and/or tissues based on PLCH-encoding nucleic acid molecules and antibodies capable of binding specifically to PLCH.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: October 14, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Jeffrey J. Seilhamer
  • Patent number: 5650280
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel cellubrevin (cb). The present invention also provides for antisense molecules to the nucleotide sequences which encode cb, expression vectors for the production of purified CB, antibodies capable of binding specifically to CB, hybridization probes or oligonucleotides for the detecting the upregulation of CB encoding nucleotide sequences, genetically engineered host cells for the expression of CB, diagnostic tests for activated, inflamed or diseased cells and/or tissues based on CB-encoding nucleic acid molecules and antibodies capable of binding specifically to CB.
    Type: Grant
    Filed: March 23, 1995
    Date of Patent: July 22, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Susan G. Stuart, Phillip R. Hawkins, Jeffrey J. Seilhamer
  • Patent number: 5637462
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a new cathepsin C homolog (RCP) expressed in THP-1 cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode RCP, expression vectors for the production of purified RCP, antibodies capable of binding specifically to RCP, hybridization probes or oligonucleotides for the detection of RCP-encoding nucleotide sequences, genetically engineered host cells for the expression of RCP, diagnostic tests for activation of monocyte/macrophages based on RCP-encoding nucleic acid molecules, and use of the protein to produce antibodies capable of binding specifically to the protein and use of the protein to screen for inhibitors.
    Type: Grant
    Filed: April 19, 1995
    Date of Patent: June 10, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Scott M. Braxton, Jeffrey J. Seilhamer
  • Patent number: 5633149
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, expression vectors for the production of purified ADEC, antibodies capable of binding specifically to ADEC, hybridization probes or oligonucleotides for the detection of ADEC-encoding nucleotide sequences, genetically engineered host cells for the expression of ADEC, diagnostic tests for inflammation or disease based on ADEC-encoding nucleic acid molecules or antibodies capable of binding specifically to ADEC.
    Type: Grant
    Filed: December 7, 1994
    Date of Patent: May 27, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Karl J. Guegler, Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 5605817
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (FSEC) from human fetal spleen cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode FSEC, expression vectors for the production of purified FSEC, antibodies capable of binding specifically to FSEC, hybridization probes or oligonucleotides for the detection of FSEC-encoding nucleotide sequences, genetically engineered host cells for the expression of FSEC, diagnostic tests for chemokine activation based on FSEC-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: February 25, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Roger Coleman, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 5602008
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (ECs) from liver and pituitary gland tissues. The present invention also provides for antisense molecules to the nucleotide sequences which encode ECs, expression vectors for the production of purified ECs, antibodies capable of binding specifically to ECs, hybridization probes or oligonucleotides for the detection of EC-encoding nucleotide sequences, genetically engineered host cells for the expression of ECs, diagnostic tests for inflammation or disease based on on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs, pharmaceutical compositions to treat inflammation or disease based on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: February 11, 1997
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Craig G. Wilde, Phillip R. Hawkins, Olga Bandman, Jeffrey J. Seilhamer
  • Patent number: 5587301
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode the hyaluronan receptor (hr) from human umbilical vein endothelial cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode hr, expression vectors for the production of purified HR, antibodies capable of binding specifically to HR, hybridization probes or oligonucleotides for the detecting the upregulation of HR encoding nucleotide sequences, genetically engineered host cells for the expression of HR, diagnostic tests for activated, angiogenic, inflamed or metastatic cells and/or tissues based on HR-encoding nucleic acid molecules and antibodies capable of binding specifically to the receptor.
    Type: Grant
    Filed: March 10, 1995
    Date of Patent: December 24, 1996
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Craig G. Wilde, Jeffrey J. Seilhamer
  • Patent number: 5587306
    Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode a novel phospholipase C homolog (plch and PLCH). The present invention also provides for antisense molecules to the plch nucleotide sequences, expression vectors for the production of purified PLCH, antibodies capable of binding specifically to PLCH, hybridization probes or oligonucleotides for the detecting excess PLCH-encoding nucleotide sequences, genetically engineered host cells for the expression of PLCH, diagnostic tests for activated, inflamed, diseased, and hydroxyurea-resistant cells and/or tissues based on PLCH-encoding nucleic acid molecules and antibodies capable of binding specifically to PLCH.
    Type: Grant
    Filed: April 10, 1995
    Date of Patent: December 24, 1996
    Assignee: Incyte Pharmaceuticals, Inc.
    Inventors: Phillip R. Hawkins, Jeffrey J. Seilhamer
  • Patent number: 5552530
    Abstract: Antibodies that specifically bind to and inhibit the enzymatic activity of synovial phospholipase A.sub.2 Type A are described. The antibodies may be used in assays for detection of synovial phospholipase A.sub.2 in biological samples.
    Type: Grant
    Filed: August 1, 1994
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly & Company
    Inventors: Lorin K. Johnson, Jeffrey J. Seilhamer, Waldemar Pruzanski, Peter Vadas
  • Patent number: 5114923
    Abstract: The cDNA sequence encoding porcine brain natriuretic peptide and related genes encoding canine and human peptides with natriuretic activity are disclosed. The gene is shown to make accessible the DNAs encoding analogous natriuretic peptides in other vertebrate species. The genes encoding these NPs can be used to effect modifications of the sequence to produce alternate forms of the NPs and to provide practical amounts of these proteins. The NPs of the invention can also be synthesized chemically. The invention peptides have the formula: ##STR1## wherein R.sup.1 is selected from the group consisting of: ##STR2## or a 10- to 109-amino acid sequence shown as the native upstream sequence for porcine, canine or human NP in FIG. 6, or a composite thereof;R.sup.2 is (OH), NH.sub.2, or NR'R" wherein R' and R" are independently lower alkyl (1-4C) or is ##STR3## or the amides (NH.sub.2 or NR'R") thereof, with the proviso that if formula (1) isR.sup.
    Type: Grant
    Filed: February 2, 1990
    Date of Patent: May 19, 1992
    Assignee: California Biotechnology Inc.
    Inventors: Jeffrey J. Seilhamer, John A. Lewicki, Robert M. Scarborough, J. Gordon Porter
  • Patent number: 5019508
    Abstract: Mammalian synovial phospholipase A.sub.2 (sPLA.sub.2) enzymes are provided, as well as DNA constructs encoding these enzymes, methods of producing the enzymes recombinantly, and antibodies thereto. Therapeutic methods employing anti-synovial phospholipase antibodies are also provided, in addition to diagnositc methods and other applications of sPLA.sub.2.
    Type: Grant
    Filed: July 6, 1988
    Date of Patent: May 28, 1991
    Assignees: Biotechnology Research Partners, Ltd., The University of Toronto Innovations Foundation
    Inventors: Lorin K. Johnson, Jeffrey J. Seilhamer, Waldemar Pruzanski, Peter Vadas